CRSP240705P51000
- 0.05
- -0.11-68.75%
CRISPR Therapeutics Newsroom
Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?
Guggenheim Assumes CRISPR Therapeutics at Neutral
Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics with a Neutral rating.
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and maintains $105 price target.
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $88
Needham analyst Gil Blum maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $88.According to TipRanks data, the analyst has a success rate of 41.0% and a tot
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
Piper Sandler analyst Edward Tenthoff maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 3
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $88 price target.
S&P 500 Futures Up In Premarket Trading; Broadcom, Tesla Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Broadcom Inc. (AVGO) was up 13.8% in pre-market tra
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
William Blair analyst Tim Lugo maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.8% and a total average return of 6.7% over th
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise
The wave of US biopharmaceutical mergers and acquisitions has set off who will be the next potential target?
The Zhitong Finance App learned that Wells Fargo released its annual list of potential mergers and acquisitions in the biopharmaceutical industry, adding diet drug developers Viking Therapeutics (VKTX.US), gene editing company CRISPR Therapeutics (CRSP.US), and Intellia Therapeutics (NTLA.US) to the list of potential acquisition targets in 2024. The investment bank has identified 31 such companies in the biopharmaceutical small to medium cap sector, and these companies are highly or moderately suitable for the following large pharmaceutical companies
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo